These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22262202)

  • 1. Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction.
    Konishi M
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):301-5. PubMed ID: 22262202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of chemotherapy in treatments for biliary tract cancer.
    Furuse J; Kasuga A; Takasu A; Kitamura H; Nagashima F
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):337-41. PubMed ID: 22456744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative adjuvant treatments for biliary tract cancer.
    Furuse J
    J Hepatobiliary Pancreat Surg; 2008; 15(5):463-7. PubMed ID: 18836797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
    Harada N; Shirabe K; Yoshizumi T; Ikegami T; Uchiyama H; Soejima Y; Yamashita Y; Saeki H; Oki E; Kawanaka H; Morita M; Ikeda T; Matsuura H; Okadome K; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Dec; 104(12):539-48. PubMed ID: 24693682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
    Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T
    Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
    Cassier PA; Thevenet C; Walter T; Baulieux J; Scoazec JY; Bancel B; Adham M; Souquet JC; Ponchon T; Lombard-Bohas C
    Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1111-7. PubMed ID: 20386107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
    Nara S; Esaki M; Ban D; Takamoto T; Shimada K; Ioka T; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2020 Dec; 50(12):1353-1363. PubMed ID: 33037430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of gemcitabine in biliary tract carcinoma.
    Scheithauer W
    Semin Oncol; 2002 Dec; 29(6 Suppl 20):40-5. PubMed ID: 12577232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of prognosis for unresectable biliary tract cancer.
    Sasaki T; Isayama H; Nakai Y; Takahara N; Sasahira N; Kogure H; Mizuno S; Yagioka H; Ito Y; Yamamoto N; Hirano K; Toda N; Tada M; Omata M; Koike K
    World J Gastroenterol; 2013 Jan; 19(1):72-7. PubMed ID: 23326165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adjuvant treatment of biliary tract cancers: Who and how?].
    Edeline J
    Bull Cancer; 2020 Jan; 107(1):48-53. PubMed ID: 31980143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biliary-tract cancer: improving therapy by adding molecularly targeted agents.
    Jensen LH
    Lancet Oncol; 2012 Feb; 13(2):118-9. PubMed ID: 22192730
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.
    Yang R; Wang B; Chen YJ; Li HB; Hu JB; Zou SQ
    Anticancer Drugs; 2013 Sep; 24(8):871-7. PubMed ID: 23799294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
    Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
    Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.
    Yamanaka K; Hatano E; Kanai M; Tanaka S; Yamamoto K; Narita M; Nagata H; Ishii T; Machimoto T; Taura K; Uemoto S
    Int J Clin Oncol; 2014; 19(3):485-9. PubMed ID: 23765238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
    Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
    Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant treatments in biliary tract cancer: an analysis based on restricted mean survival time.
    Messori A; Bartoli L; Trippoli S
    Dig Liver Dis; 2020 Oct; 52(10):1208-1209. PubMed ID: 32505564
    [No Abstract]   [Full Text] [Related]  

  • 20. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.